Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
besipirdine
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Besipirdine (HP749) is a small molecule dual-acting agent that functions as an alpha-2 adrenergic receptor antagonist and a monoamine reuptake inhibitor, specifically targeting norepinephrine and serotonin transporters. Originally developed by Hoechst-Roussel for the treatment of Alzheimer's disease due to its neuromodulatory effects, it was later licensed and developed by UroGene SA for the treatment of overactive bladder (OAB). In the context of OAB, the drug was intended to improve bladder storage and reduce involuntary contractions by modulating neurotransmission. Despite reaching Phase 2 clinical trials for OAB, including randomized placebo-controlled studies at 20 mg doses, development was discontinued. UroGene was eventually acquired by Pierre Fabre in 2004, and the program did not proceed to further stages.
- Other names
- besipirdine hydrochloride
02
Targets
NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)ADRA2A (α2A)
Beyond the preview
Go deeper on besipirdine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on besipirdine.